Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.

Baseline Mucin-1 and Pulmonary Function Decline Following the initiation of pirfenidone treatment, there was an overall pattern of reduction in the annualized decline in both FVC and D LCO in the study cohort, although these differences did not reach statistical significance ( Figure 5 a,b).

also in 111,027 other papers